vs
ANI PHARMACEUTICALS INC（ANIP）とPOWELL INDUSTRIES INC（POWL）の財務データ比較。上の社名をクリックして会社を切り替えられます
POWELL INDUSTRIES INCの直近四半期売上が大きい（$251.2M vs $247.1M、ANI PHARMACEUTICALS INCの約1.0倍）。POWELL INDUSTRIES INCの純利益率が高く（16.5% vs 11.1%、差は5.4%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 4.0%）。POWELL INDUSTRIES INCの直近四半期フリーキャッシュフローが多い（$41.6M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -0.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Powell Industries, Inc.は1947年に設立され、テキサス州ヒューストンに本社を置く企業で、商業・産業分野向けに電力分配の監視・制御用の統合パッケージソリューション及び電気機器を製造・提供しています。
ANIP vs POWL — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $251.2M |
| 純利益 | $27.5M | $41.4M |
| 粗利率 | — | 28.4% |
| 営業利益率 | 14.1% | 17.0% |
| 純利益率 | 11.1% | 16.5% |
| 売上前年比 | 29.6% | 4.0% |
| 純利益前年比 | 367.5% | 19.1% |
| EPS（希薄化後） | $1.14 | $3.40 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $251.2M | ||
| Q3 25 | $227.8M | $298.0M | ||
| Q2 25 | $211.4M | $286.3M | ||
| Q1 25 | $197.1M | $278.6M | ||
| Q4 24 | $190.6M | $241.4M | ||
| Q3 24 | $148.3M | $275.1M | ||
| Q2 24 | $138.0M | $288.2M | ||
| Q1 24 | $137.4M | $255.1M |
| Q4 25 | $27.5M | $41.4M | ||
| Q3 25 | $26.6M | $51.4M | ||
| Q2 25 | $8.5M | $48.2M | ||
| Q1 25 | $15.7M | $46.3M | ||
| Q4 24 | $-10.3M | $34.8M | ||
| Q3 24 | $-24.2M | $46.1M | ||
| Q2 24 | $-2.3M | $46.2M | ||
| Q1 24 | $18.2M | $33.5M |
| Q4 25 | — | 28.4% | ||
| Q3 25 | — | 31.4% | ||
| Q2 25 | — | 30.7% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 24.7% | ||
| Q3 24 | — | 29.2% | ||
| Q2 24 | — | 28.4% | ||
| Q1 24 | — | 24.6% |
| Q4 25 | 14.1% | 17.0% | ||
| Q3 25 | 15.9% | 21.2% | ||
| Q2 25 | 6.6% | 21.0% | ||
| Q1 25 | 13.3% | 21.1% | ||
| Q4 24 | -2.3% | 14.7% | ||
| Q3 24 | -13.8% | 20.4% | ||
| Q2 24 | 3.7% | 19.9% | ||
| Q1 24 | 14.8% | 15.5% |
| Q4 25 | 11.1% | 16.5% | ||
| Q3 25 | 11.7% | 17.3% | ||
| Q2 25 | 4.0% | 16.8% | ||
| Q1 25 | 8.0% | 16.6% | ||
| Q4 24 | -5.4% | 14.4% | ||
| Q3 24 | -16.3% | 16.7% | ||
| Q2 24 | -1.7% | 16.0% | ||
| Q1 24 | 13.2% | 13.1% |
| Q4 25 | $1.14 | $3.40 | ||
| Q3 25 | $1.13 | $4.23 | ||
| Q2 25 | $0.36 | $3.96 | ||
| Q1 25 | $0.69 | $3.81 | ||
| Q4 24 | $-0.45 | $2.86 | ||
| Q3 24 | $-1.27 | $3.77 | ||
| Q2 24 | $-0.14 | $3.79 | ||
| Q1 24 | $0.82 | $2.75 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $500.8M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $668.9M |
| 総資産 | $1.4B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $500.8M | ||
| Q3 25 | $262.6M | $475.5M | ||
| Q2 25 | $217.8M | $433.0M | ||
| Q1 25 | $149.8M | $389.3M | ||
| Q4 24 | $144.9M | $373.4M | ||
| Q3 24 | $145.0M | $358.4M | ||
| Q2 24 | $240.1M | $374.0M | ||
| Q1 24 | $228.6M | $365.3M |
| Q4 25 | $540.7M | $668.9M | ||
| Q3 25 | $505.8M | $640.8M | ||
| Q2 25 | $436.8M | $594.9M | ||
| Q1 25 | $418.6M | $541.4M | ||
| Q4 24 | $403.7M | $496.3M | ||
| Q3 24 | $405.9M | $483.1M | ||
| Q2 24 | $455.8M | $436.7M | ||
| Q1 24 | $452.0M | $393.8M |
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $965.4M | ||
| Q4 24 | $1.3B | $912.7M | ||
| Q3 24 | $1.3B | $928.2M | ||
| Q2 24 | $920.8M | $869.0M | ||
| Q1 24 | $914.5M | $849.6M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $43.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $41.6M |
| FCFマージンFCF / 売上 | 11.8% | 16.6% |
| 設備投資強度設備投資 / 売上 | 0.5% | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.05× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $161.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $43.6M | ||
| Q3 25 | $44.1M | $61.1M | ||
| Q2 25 | $75.8M | $47.4M | ||
| Q1 25 | $35.0M | $22.4M | ||
| Q4 24 | $15.9M | $37.1M | ||
| Q3 24 | $12.5M | $-6.0M | ||
| Q2 24 | $17.4M | $13.8M | ||
| Q1 24 | $18.3M | $17.0M |
| Q4 25 | $29.1M | $41.6M | ||
| Q3 25 | $38.0M | $59.3M | ||
| Q2 25 | $71.8M | $42.3M | ||
| Q1 25 | $32.5M | $18.3M | ||
| Q4 24 | $13.5M | $34.9M | ||
| Q3 24 | $7.7M | $-14.4M | ||
| Q2 24 | $13.0M | $12.4M | ||
| Q1 24 | $13.7M | $16.1M |
| Q4 25 | 11.8% | 16.6% | ||
| Q3 25 | 16.7% | 19.9% | ||
| Q2 25 | 34.0% | 14.8% | ||
| Q1 25 | 16.5% | 6.6% | ||
| Q4 24 | 7.1% | 14.4% | ||
| Q3 24 | 5.2% | -5.3% | ||
| Q2 24 | 9.4% | 4.3% | ||
| Q1 24 | 10.0% | 6.3% |
| Q4 25 | 0.5% | 0.8% | ||
| Q3 25 | 2.7% | 0.6% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.3% | 0.9% | ||
| Q3 24 | 3.2% | 3.1% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.4% |
| Q4 25 | 1.10× | 1.05× | ||
| Q3 25 | 1.66× | 1.19× | ||
| Q2 25 | 8.87× | 0.98× | ||
| Q1 25 | 2.23× | 0.48× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | -0.13× | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | 1.00× | 0.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
POWL
| Oil And Gas Service | $97.9M | 39% |
| Electricity | $69.3M | 28% |
| Commercial And Other Industrial | $40.6M | 16% |
| Petrochemical | $22.8M | 9% |
| Other Customers | $12.0M | 5% |
| Light Rail Traction Power Customer | $8.6M | 3% |
